An Open-label Study of Efficacy, Safety and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily in Addition to Standard Multi-antibiotic Therapy in the Treatment of Mycobacterium Abscessus Lung Disease

Trial Profile

An Open-label Study of Efficacy, Safety and Tolerability of Liposomal Amikacin for Inhalation (LAI) Once Daily in Addition to Standard Multi-antibiotic Therapy in the Treatment of Mycobacterium Abscessus Lung Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Amikacin (Primary)
  • Indications Mycobacterial infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2018 Planned End Date changed from 1 Dec 2019 to 1 Jun 2019.
    • 25 Jun 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Mar 2019.
    • 25 Jun 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top